ATAI Life Sciences N.V. (ATAI, Financial) experienced a significant stock drop of 5.52%, with shares priced at $1.54. The trading volume reached 732,560 shares, reflecting a turnover rate of 0.44% and a price fluctuation of 9.51%. Recent financial reports indicate revenue of $40,000, a net loss of $26.29 million, and an earnings per share of -$0.16, with a gross profit of -$43,000 and a P/E ratio of -1.94. Currently, no institutional ratings are available for this stock.
In the biotechnology sector, where ATAI operates, the overall growth was 0.18%. Notable performers include Cyclerion Therapeutics, Inc. and Nls Pharmaceutics Ltd, which showed significant stock activity and volatility.
